+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Influenzavirus B Infections (Infectious Disease) - Drugs In Development, 2021

  • ID: 5402674
  • Report
  • July 2021
  • Region: Global
  • 212 Pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

FEATURED COMPANIES

  • AbbVie Inc
  • Adimmune Corp
  • Ansun Biopharma Inc
  • AstraZeneca Plc
  • Biotron Ltd
  • Cidara Therapeutics Inc
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Influenzavirus B Infections - Drugs In Development, 2021, provides an overview of the Influenzavirus B Infections (Infectious Disease) pipeline landscape.

Type B influenza is a subtype of the influenza virus that tends to occur sporadically. Symptoms include runny nose, sore throat, aching muscles, malaise, watery eyes, aching body, loss of appetite and weakness. Treatment includes antiviral, analgesics and antipyretics medications.

Report Highlights


The publisher's Pharmaceutical and Healthcare latest pipeline guide Influenzavirus B Infections - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Influenzavirus B Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Influenzavirus B Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Influenzavirus B Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 6, 10, 8, 9, 25 and 6 respectively. Similarly, the Universities portfolio in Phase III, Phase I, Preclinical and Discovery stages comprises 3, 1, 1 and 2 molecules, respectively.

Influenzavirus B Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Influenzavirus B Infections (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Influenzavirus B Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Influenzavirus B Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Influenzavirus B Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Influenzavirus B Infections (Infectious Disease)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Influenzavirus B Infections (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Influenzavirus B Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • AbbVie Inc
  • Adimmune Corp
  • Ansun Biopharma Inc
  • AstraZeneca Plc
  • Biotron Ltd
  • Cidara Therapeutics Inc
Introduction
Influenzavirus B Infections - Overview
  • Influenzavirus B Infections - Therapeutics Development
Influenzavirus B Infections - Therapeutics Assessment
Influenzavirus B Infections - Companies Involved in Therapeutics Development
Influenzavirus B Infections - Drug Profiles
Influenzavirus B Infections - Dormant Projects
Influenzavirus B Infections - Discontinued Products
Influenzavirus B Infections - Product Development Milestones
Appendix

List of Tables
  • Number of Products under Development for Influenzavirus B Infections, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Products under Development by Companies, 2021
  • Products under Development by Universities/Institutes, 2021
  • Number of Products by Stage and Target, 2021
  • Number of Products by Stage and Mechanism of Action, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Influenzavirus B Infections - Pipeline by AbbVie Inc, 2021
  • Influenzavirus B Infections - Pipeline by Abhelix LLC, 2021
  • Influenzavirus B Infections - Pipeline by Adimmune Corp, 2021
  • Influenzavirus B Infections - Pipeline by Allergy Therapeutics Plc, 2021
  • Influenzavirus B Infections - Pipeline by Ansun Biopharma Inc, 2021
  • Influenzavirus B Infections - Pipeline by Aphios Corp, 2021
  • Influenzavirus B Infections - Pipeline by AstraZeneca Plc, 2021
  • Influenzavirus B Infections - Pipeline by AusBio Ltd, 2021
  • Influenzavirus B Infections - Pipeline by Biotron Ltd, 2021
  • Influenzavirus B Infections - Pipeline by BlueWillow Biologics Inc, 2021
  • Influenzavirus B Infections - Pipeline by Cidara Therapeutics Inc, 2021
  • Influenzavirus B Infections - Pipeline by Cocrystal Pharma Inc, 2021
  • Influenzavirus B Infections - Pipeline by ContraFect Corp, 2021
  • Influenzavirus B Infections - Pipeline by CSL Ltd, 2021
  • Influenzavirus B Infections - Pipeline by DAE HWA Pharmaceutical Co Ltd, 2021
  • Influenzavirus B Infections - Pipeline by e-Therapeutics Plc, 2021
  • Influenzavirus B Infections - Pipeline by Evotec SE, 2021
  • Influenzavirus B Infections - Pipeline by Evrys Bio, 2021
  • Influenzavirus B Infections - Pipeline by FUJIFILM Toyama Chemical Co Ltd, 2021
  • Influenzavirus B Infections - Pipeline by Ginkgo Tree Pharmaceutical (Suzhou) Co Ltd, 2021
  • Influenzavirus B Infections - Pipeline by Hangzhou Zenshine Pharmaceuticals Co Ltd, 2021
  • Influenzavirus B Infections - Pipeline by Imutex Ltd, 2021
  • Influenzavirus B Infections - Pipeline by Inovio Pharmaceuticals Inc, 2021
  • Influenzavirus B Infections - Pipeline by Institute of Virology Vaccines and Sera Torlak, 2021
  • Influenzavirus B Infections - Pipeline by iQur Ltd, 2021
  • Influenzavirus B Infections - Pipeline by Jiangsu Ab&b Biotechnology Co Ltd, 2021
  • Influenzavirus B Infections - Pipeline by Jiangsu Carephar Pharmaceutical Co Ltd, 2021
  • Influenzavirus B Infections - Pipeline by Johnson & Johnson, 2021
  • Influenzavirus B Infections - Pipeline by Kentucky BioProcessing Inc, 2021
  • Influenzavirus B Infections - Pipeline by Liaoning Cheng Da Biotechnology Co Ltd, 2021
  • Influenzavirus B Infections - Pipeline by Medicago Inc, 2021
  • Influenzavirus B Infections - Pipeline by Moderna Inc, 2021
  • Influenzavirus B Infections - Pipeline by Novavax Inc, 2021
  • Influenzavirus B Infections - Pipeline by Osivax SAS, 2021
  • Influenzavirus B Infections - Pipeline by Park Active Molecules, 2021
  • Influenzavirus B Infections - Pipeline by Pentavalent Bio Sciences Pvt Ltd, 2021
  • Influenzavirus B Infections - Pipeline by Revelation Biosciences Inc, 2021
  • Influenzavirus B Infections - Pipeline by Romark Laboratories LC, 2021
  • Influenzavirus B Infections - Pipeline by SAB Biotherapeutics Inc, 2021
  • Influenzavirus B Infections - Pipeline by Sanofi, 2021
  • Influenzavirus B Infections - Pipeline by Sciogen Inc, 2021
  • Influenzavirus B Infections - Pipeline by Seqirus Ltd, 2021
  • Influenzavirus B Infections - Pipeline by Serum Institute of India Pvt Ltd, 2021
  • Influenzavirus B Infections - Pipeline by Shanghai Institute of Biological Products Co Ltd, 2021
  • Influenzavirus B Infections - Pipeline by Shionogi & Co Ltd, 2021
  • Influenzavirus B Infections - Pipeline by Symvivo Inc, 2021
  • Influenzavirus B Infections - Pipeline by TaiGen Biotechnology Co Ltd, 2021
  • Influenzavirus B Infections - Pipeline by Therapeutic Systems Research Laboratories Inc, 2021
  • Influenzavirus B Infections - Pipeline by Trellis Bioscience Inc, 2021
  • Influenzavirus B Infections - Pipeline by Tria Bioscience Corp, 2021
  • Influenzavirus B Infections - Pipeline by UMN Pharma Inc, 2021
  • Influenzavirus B Infections - Pipeline by Vacthera BioTech GmbH, 2021
  • Influenzavirus B Infections - Pipeline by Ventaleon GmbH, 2021
  • Influenzavirus B Infections - Pipeline by Viramatix Sdn Bhd, 2021
  • Influenzavirus B Infections - Pipeline by Walvax Biotechnology Co Ltd, 2021
  • Influenzavirus B Infections - Pipeline by Wuhan Institute of Biological Products Co Ltd, 2021
  • Influenzavirus B Infections - Dormant Projects, 2021
  • Influenzavirus B Infections - Discontinued Products, 2021
List of Figures
  • Number of Products under Development for Influenzavirus B Infections, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Number of Products by Top 10 Targets, 2021
  • Number of Products by Stage and Top 10 Targets, 2021
  • Number of Products by Top 10 Mechanism of Actions, 2021
  • Number of Products by Stage and Top 10 Mechanism of Actions, 2021
  • Number of Products by Top 10 Routes of Administration, 2021
  • Number of Products by Stage and Top 10 Routes of Administration, 2021
  • Number of Products by Top 10 Molecule Types, 2021
  • Number of Products by Stage and Top 10 Molecule Types, 2021
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • AbbVie Inc
  • Abhelix LLC
  • Adimmune Corp
  • Allergy Therapeutics Plc
  • Ansun Biopharma Inc
  • Aphios Corp
  • AstraZeneca Plc
  • AusBio Ltd
  • Biotron Ltd
  • BlueWillow Biologics Inc
  • Cidara Therapeutics Inc
  • Cocrystal Pharma Inc
  • ContraFect Corp
Note: Product cover images may vary from those shown
Adroll
adroll